A COG Pilot Study of Intensive Induction Therapy and 131I-MIBG With Myeloablative Carboplatin, Etoposide and Melphalan (CEM) for Newly Diagnosed High-Risk Neuroblastoma.
Latest Information Update: 10 Jan 2025
At a glance
- Drugs Busulfan (Primary) ; Cisplatin (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Etoposide phosphate (Primary) ; Iobenguane (Primary) ; Isotretinoin (Primary) ; Melphalan (Primary) ; Topotecan (Primary) ; Vincristine (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions; Pharmacogenomic
Most Recent Events
- 07 Jan 2025 Planned End Date changed from 28 Sep 2024 to 28 Sep 2025.
- 26 Dec 2023 Planned End Date changed from 28 Sep 2023 to 28 Sep 2024.
- 07 Mar 2023 Planned End Date changed from 1 Dec 2015 to 28 Sep 2023.